Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ:ELDN
Want to see ELDN full AI Analyst Report?
Total Valuation
Eledon Pharmaceuticals has a market cap or net worth of $276.33M. The enterprise value is $209.02M.
Market Cap$276.33M
Enterprise Value$209.02M
Share Statistics
Eledon Pharmaceuticals has 77,187,820 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,187,820
Owned by Insiders0.03%
Owned by Institutions29.01%
Financial Efficiency
Eledon Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -55.12%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-55.12%
Return on Capital Employed (ROCE)-0.55
Revenue Per Employee0.00
Profits Per Employee-1.47M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eledon Pharmaceuticals is ―. Eledon Pharmaceuticals’s PEG ratio is 0.11.
PE Ratio―
PS Ratio0.00
PB Ratio1.52
Price to Fair Value1.52
Price to FCF-1.98
Price to Operating Cash Flow-5.84
PEG Ratio0.11
Income Statement
In the last 12 months, Eledon Pharmaceuticals had revenue of 0.00 and earned -45.62M in profits. Earnings per share was -0.56.
Revenue0.00
Gross Profit0.00
Operating Income-83.25M
Pretax Income-45.58M
Net Income-45.62M
EBITDA-83.25M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was -68.89M and capital expenditures 0.00, giving a free cash flow of -68.89M billion.
Operating Cash Flow-68.89M
Free Cash Flow-68.89M
Free Cash Flow per Share-0.89
Dividends & Yields
Eledon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.43
52-Week Price Change13.65%
50-Day Moving Average3.34
200-Day Moving Average2.62
Relative Strength Index (RSI)48.55
Average Volume (3m)1.59M
Important Dates
Eledon Pharmaceuticals upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Eledon Pharmaceuticals as a current ratio of 7.40, with Debt / Equity ratio of 0.55%
Current Ratio7.40
Quick Ratio7.40
Debt to Market Cap0.00
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Eledon Pharmaceuticals has paid 35.00K in taxes.
Income Tax35.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Eledon Pharmaceuticals EV to EBITDA ratio is -1.22, with an EV/FCF ratio of -1.63.
EV to Sales0.00
EV to EBITDA-1.22
EV to Free Cash Flow-1.63
EV to Operating Cash Flow-1.63
Balance Sheet
Eledon Pharmaceuticals has $111.09M in cash and marketable securities with $555.00K in debt, giving a net cash position of $110.53M billion.
Cash & Marketable Securities$111.09M
Total Debt$555.00K
Net Cash$110.53M
Net Cash Per Share$1.43
Tangible Book Value Per Share$0.60
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eledon Pharmaceuticals is $8.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.00
Price Target Upside101.01% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-1.48%